



**BRAINSWAY LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**U.S. dollars in thousands**

	<b>March 31,</b>	<b>December 31,</b>
	<b>2023</b>	<b>2022</b>
<u>ASSETS</u>	<u>(Unaudited)</u>	
<b>Current Assets</b>		
Cash and cash equivalents	\$ 44,051	\$ 47,581
Short-term deposits	271	271
Trade receivables, net	5,350	4,844
Inventory	4,736	3,837
Other current assets	1,738	1,556
	56,146	58,089
<b>Non-Current Assets</b>		
System components	483	1,220
Leased systems, net	3,315	3,118
Other property and equipment	947	1,008
Other long-term assets	1,064	1,042
	5,809	6,388
	\$ 61,955	\$ 64,477
<u>LIABILITIES AND EQUITY</u>		
<b>Current Liabilities</b>		
Trade payables	\$ 584	\$ 1,116
Deferred revenues	2,263	1,477
Liability in respect of research and development grants	1,158	1,057
Other accounts payable	5,159	4,491
	9,164	8,141
<b>Non-Current Liabilities</b>		
Deferred revenues and other liabilities	4,766	4,923
Liability in respect of research and development grants	5,108	6,016
	9,874	10,939
<b>Equity</b>		
Share capital	364	364
Share premium	138,146	138,146
Share-based payment reserve	6,132	6,180
Currency Translation Adjustments	(2,188)	(2,188)
Accumulated deficit	(99,537)	(97,105)
	42,917	45,397
	\$ 61,955	\$ 64,477



**BRAINSWAY LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**  
U.S. dollars in thousands (except per share data)

	<b>For the three months ended</b>	
	<b>March 31,</b>	
	<b>2023</b>	<b>2022</b>
	<b>(Unaudited)</b>	
Revenues	\$ 6,625	\$ 7,970
Cost of revenues	1,792	1,867
Gross profit	<u>4,833</u>	<u>6,103</u>
Selling and marketing expenses	4,912	4,146
Research and development expenses, net	1,785	1,576
General and administrative expenses	1,803	1,863
Total operating expenses	<u>8,500</u>	<u>7,585</u>
Operating loss	(3,667)	(1,482)
Finance income (expense), net	<u>1,407</u>	<u>(324)</u>
Loss before income taxes	(2,260)	(1,806)
Taxes on income	171	187
Net loss and total comprehensive loss	<u>\$ (2,431)</u>	<u>\$ (1,993)</u>
Basic and diluted net loss per share	<u>\$ (0.07)</u>	<u>\$ (0.05)</u>



**BRAINSWAY LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
U.S. dollars in thousands

	<b>For the three months ended</b>	
	<b>March 31,</b>	
	<b>2023</b>	<b>2022</b>
	<b>(Unaudited)</b>	
Cash flows from operating activities:		
Total comprehensive loss	\$ (2,431)	\$ (1,993)
Adjustments to reconcile net loss to net cash used in operating activities:		
Adjustments to profit or loss items:		
Depreciation and amortization	93	142
Depreciation of leased systems	233	245
Impairments and disposals	246	(68)
Finance expenses, net	(1,471)	324
Cost of share based payment	(51)	374
Income taxes	171	187
Total adjustments to reconcile loss	<u>(779)</u>	<u>1,204</u>
Changes in asset and liability items:		
Increase in trade receivables	(493)	(63)
Increase in inventory	(928)	(1,313)
Increase in other accounts receivable	(222)	(61)
Decrease in trade payables	(535)	(512)
Increase (decrease) in other accounts payable	511	(510)
Increase in deferred revenues and other liabilities	700	273
Total changes in asset and liability	<u>(967)</u>	<u>(2,186)</u>
Cash paid and received during the period for:		
Interest paid	(31)	(12)
Interest received	674	3
Income taxes paid	(7)	(3)
Total cash paid and received during the period	<u>636</u>	<u>(12)</u>
Net cash provided by (used in) operating activities:	<u>(3,541)</u>	<u>(2,987)</u>
Cash flows from investing activities:		
Proceeds from property and equipment and system components, net	66	951
Withdrawal of (investment in) short-term deposits, net	-	(50)
Investment in long-term deposits, net	(2)	(3)
Net cash provided by (used in) investing activities	<u>64</u>	<u>898</u>
Cash flows from financing activities:		
Repayment of liability in respect of research and development grants	-	(498)
Receipt of government grants	-	6
Repayment of lease liability	(66)	(148)
Issuance of share capital, net	-	1
Net cash used in financing activities	<u>(66)</u>	<u>(639)</u>
Exchange rate differences on cash and cash equivalents	<u>13</u>	<u>(88)</u>
Decrease in cash and cash equivalents	(3,530)	(2,816)
Cash and cash equivalents at the beginning of the period	47,581	16,921
Cash and cash equivalents at the end of the period	<u>\$ 44,051</u>	<u>\$ 14,105</u>
(a) Significant non cash transactions:		
Recognition of new lease liability and right-of-use	<u>24</u>	<u>-</u>
Termination of lease liability and right-of-use	<u>11</u>	<u>-</u>